News

ANA773 is the company’s investigational oral TLR7 agonist prodrug. In part B of the study, patients in the first cohort will receive 800mg of ANA773 every other day

Mr Still has been serving in the capacity of president and COO for the company since earlier 2008. Prior to Accumetrics, Mr Still was executive vice president and

The test uses Roche’s real-time polymerase chain reaction technology to quantify the amount of hepatitis C RNA in a patient’s blood. The new test offers a broad dynamic

The license agreement also includes Monebo’s call center management software. Bioheart plans to immediately begin selling the CardioBelt system worldwide, including the US market, as a complementary technology

Final results from the study confirmed the positive interim results announced in July 2008 that significantly higher anti-nicotine antibody levels can be generated three months earlier and in

In this study, designed to show equivalent rate of change in bone mineral density (BMD) for Advair and salmeterol, results for bone mineral density in the lumbar spine

In this study, researchers found that Vyvanse controlled attention deficit hyperactivity disorder (ADHD) symptoms from the first time point measured (1.5 hours) through the last time point assessed

The company has also requested priority review, based on the potential for PolyHeme to address a critical, unmet medical need. By regulation, the FDA has 60 calendar days

The Flair endovascular stent graft, comprised of a self-expanding nitinol stent encapsulated within Bard’s proprietary ePTFE graft material, is marketed by the Bard Peripheral Vascular division located in